215 related articles for article (PubMed ID: 12853747)
1. Prevalence and characterization of lamivudine-resistant hepatitis B virus mutations in HIV-HBV co-infected individuals.
Cooley L; Ayres A; Bartholomeusz A; Lewin S; Crowe S; Mijch A; Locarnini S; Sasadeusz J
AIDS; 2003 Jul; 17(11):1649-57. PubMed ID: 12853747
[TBL] [Abstract][Full Text] [Related]
2. Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy.
Matthews GV; Bartholomeusz A; Locarnini S; Ayres A; Sasaduesz J; Seaberg E; Cooper DA; Lewin S; Dore GJ; Thio CL
AIDS; 2006 Apr; 20(6):863-70. PubMed ID: 16549970
[TBL] [Abstract][Full Text] [Related]
3. High incidence of lamivudine-resistance-associated vaccine-escape HBV mutants among HIV-coinfected patients on prolonged antiretroviral therapy.
Pal A; Sarkar N; Saha D; Guha SK; Saha B; Chakrabarti S; Chakravarty R
Antivir Ther; 2015; 20(5):545-54. PubMed ID: 25654813
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis B genotype G and high frequency of lamivudine-resistance mutations among human immunodeficiency virus/hepatitis B virus co-infected patients in Brazil.
Silva AC; Spina AM; Lemos MF; Oba IT; Guastini Cde F; Gomes-Gouvêa MS; Pinho JR; Mendes-Correa MC
Mem Inst Oswaldo Cruz; 2010 Sep; 105(6):770-8. PubMed ID: 20944991
[TBL] [Abstract][Full Text] [Related]
5. High frequency of lamivudine resistance mutations in Brazilian patients co-infected with HIV and hepatitis B.
Mendes-Correa MC; Pinho JR; Locarnini S; Yuen L; Sitnik R; Santana RA; Gomes-Gouvêa MS; Leite OM; Martins LG; Silva MH; Gianini RJ; Uip DE
J Med Virol; 2010 Sep; 82(9):1481-8. PubMed ID: 20648600
[TBL] [Abstract][Full Text] [Related]
6. Prolonged use of tenofovir in HIV/hepatitis B virus (HBV)-coinfected individuals does not lead to HBV polymerase mutations and is associated with persistence of lamivudine HBV polymerase mutations.
Audsley J; Arrifin N; Yuen LK; Ayres A; Crowe SM; Bartholomeusz A; Locarnini SA; Mijch A; Lewin SR; Sasadeusz J
HIV Med; 2009 Apr; 10(4):229-35. PubMed ID: 19178592
[TBL] [Abstract][Full Text] [Related]
7. Hepatitis B virus drug resistance in HIV-1-infected patients taking lamivudine-containing antiretroviral therapy.
Wongprasit P; Manosuthi W; Kiertiburanakul S; Sungkanuparph S
AIDS Patient Care STDS; 2010 Apr; 24(4):205-9. PubMed ID: 20377434
[TBL] [Abstract][Full Text] [Related]
8. Effect of HIV co-infection on mutation patterns of HBV in patients with lamivudine-resistant chronic hepatitis B.
Iacomi F; Vincenti D; Vairo F; Solmone M; Mariano A; Piselli P; Puro V; Capobianchi MR; Antonucci G
J Med Virol; 2009 Jul; 81(7):1151-6. PubMed ID: 19475624
[TBL] [Abstract][Full Text] [Related]
9. Analysis of HBV basal core promoter/precore gene variability in patients with HBV drug resistance and HIV co-infection in Northwest Ethiopia.
Belyhun Y; Liebert UG; Maier M
PLoS One; 2018; 13(2):e0191970. PubMed ID: 29408943
[TBL] [Abstract][Full Text] [Related]
10. Evolution of lamivudine-resistant hepatitis B virus and HIV-1 in co-infected individuals: an analysis of the CAESAR study. CAESAR co-ordinating committee.
Pillay D; Cane PA; Ratcliffe D; Atkins M; Cooper D
AIDS; 2000 Jun; 14(9):1111-6. PubMed ID: 10894274
[TBL] [Abstract][Full Text] [Related]
11. Patterns of hepatitis B virus infection in Brazilian human immunodeficiency virus infected patients: high prevalence of occult infection and low frequency of lamivudine resistant mutations.
Sucupira MV; Mello FC; Santos EA; Niel C; Rolla VC; Arabe J; Gomes SA
Mem Inst Oswaldo Cruz; 2006 Sep; 101(6):655-60. PubMed ID: 17072479
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis B virus variants in an HIV-HBV co-infected patient at different periods of antiretroviral treatment with and without lamivudine.
Santos EA; Sucupira MV; Arabe J; Gomes SA
BMC Infect Dis; 2004 Aug; 4():29. PubMed ID: 15339340
[TBL] [Abstract][Full Text] [Related]
13. Mutations associated with lamivudine-resistance in therapy-naïve hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients.
Selabe SG; Lukhwareni A; Song E; Leeuw YG; Burnett RJ; Mphahlele MJ
J Med Virol; 2007 Nov; 79(11):1650-4. PubMed ID: 17854040
[TBL] [Abstract][Full Text] [Related]
14. The burden of hepatitis B virus (HBV) infection, genotypes and drug resistance mutations in human immunodeficiency virus-positive patients in Northwest Ethiopia.
Deressa T; Damtie D; Fonseca K; Gao S; Abate E; Alemu S; Aleka Y; Swain MG; van Marle G; Coffin CS
PLoS One; 2017; 12(12):e0190149. PubMed ID: 29281718
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis B virus genotypes and lamivudine resistance mutations in HIV/hepatitis B virus-coinfected patients.
Ramos B; Núñez M; Martín-Carbonero L; Sheldon J; Rios P; Labarga P; Romero M; Barreiro P; García-Samaniego J; Soriano V
J Acquir Immune Defic Syndr; 2007 Apr; 44(5):557-61. PubMed ID: 17224847
[TBL] [Abstract][Full Text] [Related]
16. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.
Lada O; Benhamou Y; Cahour A; Katlama C; Poynard T; Thibault V
Antivir Ther; 2004 Jun; 9(3):353-63. PubMed ID: 15259898
[TBL] [Abstract][Full Text] [Related]
17. Predominance of Hepatitis B Virus Genotype A Among Treated HIV Infected Patients Experiencing High Hepatitis B Virus Drug Resistance in Nairobi, Kenya.
Mabeya SN; Ngugi C; Lihana RW; Khamadi SA; Nyamache AK
AIDS Res Hum Retroviruses; 2017 Sep; 33(9):966-969. PubMed ID: 28316253
[TBL] [Abstract][Full Text] [Related]
18. Prevalence and resistance pattern of genotype G and H in chronic hepatitis B and HIV co-infected patients in Mexico.
Mata Marín JA; Arroyo Anduiza CI; Calderón GM; Cazares Rodríguez S; Fuentes Allen JL; Arias Flores R; Gaytán Martínez J
Ann Hepatol; 2012; 11(1):47-51. PubMed ID: 22166560
[TBL] [Abstract][Full Text] [Related]
19. Hepatitis B virus drug resistance mutations in HIV/HBV co-infected children in Windhoek, Namibia.
Tamandjou Tchuem CR; Brandt L; Nel ER; Cotton MF; Matthews P; Kaindjee-Tjituka F; Preiser W; Andersson MI
PLoS One; 2020; 15(9):e0238839. PubMed ID: 32915862
[TBL] [Abstract][Full Text] [Related]
20. HIV-HBV coinfection in Southern Africa and the effect of lamivudine- versus tenofovir-containing cART on HBV outcomes.
Hamers RL; Zaaijer HL; Wallis CL; Siwale M; Ive P; Botes ME; Sigaloff KC; Hoepelman AI; Stevens WS; Rinke de Wit TF;
J Acquir Immune Defic Syndr; 2013 Oct; 64(2):174-82. PubMed ID: 23892239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
